† The performance of the third-generation FloTrac/ Vigileo in measuring cardiac index (CI) was assessed in critically ill patients undergoing volume expansion or changes in norepinephrine dose. † This device was moderately reliable for tracking volume-induced changes in CI, but poorly reliable with norepinephrine dose titration.
Background. The ability of the third-generation FloTrac/Vigileo software to track changes in cardiac index (CI) induced by volume expansion and norepinephrine in critically ill patients is unknown.
Methods. In subjects with circulatory failure, we administered volume expansion (20 subjects) and increased (20 subjects) or decreased (20 subjects) the dose of norepinephrine. We measured arterial pressure waveform-derived CI provided by the third-generation FloTrac/Vigileo device (CI pw ) and transpulmonary thermodilution CI (CI td ) before and after therapeutic interventions.
Results. Considering the pairs of measurements performed before and after all therapeutic interventions (n¼60), a bias between the absolute values of CI pw and CI td was 0. 26 The concordance rates between changes in CI pw and CI td induced by volume expansion and norepinephrine were 73% and 60%, respectively. The bias between changes in CI pw and CI td significantly correlated with changes in total systemic vascular resistance (r 2 ¼0.41, P,0.0001).
Conclusions. The third-generation FloTrac/Vigileo device was moderately reliable for tracking changes in CI induced by volume expansion and poorly reliable for tracking changes in CI induced by norepinephrine.
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In recent years, efforts have been made to develop devices that allow beat-to-beat estimation of cardiac output (CO). Some of these systems compute CO from the arterial pressure waveform, using the principle that stroke volume is physiologically related to arterial pressure, aortic compliance, and arterial tone. 1 In particular, some 'uncalibrated' devices estimate aortic compliance and arterial tone from an analysis of the geometric properties of arterial shape and from some patient characteristic data. These devices are in contrast to some 'calibrated' systems, which add to this continuous estimation of CO an external calibration by a reference technique.
The uncalibrated systems have the great advantage of not requiring a specific system for recalibrating CO measurement. Nevertheless, their ability to track changes in CO has been questioned, 2 -9 especially when arterial tone changes to a large extent 3 or during hyperdynamic states. 7 8 10 In a previous study, we suggested that the second-generation FloTrac/Vigileo w device had a poor ability for tracking changes in cardiac index (CI) induced by norepinephrine in septic patients. 11 We hypothesized that changes in arterial compliance and arterial tone induced by the vasopressor dissystem has been demonstrated to be as precise, more accurate, and less influenced by systemic vascular resistance (SVR) than the previous version. 12 The third-generation system was not better than the second for detecting significant changes in CI over time, 12 but these changes were not induced by systematic therapeutic interventions. Moreover, a recent study suggested that the third version of the FloTrac/Vigileo device does not accurately track changes in CO induced with phenylephrine and ephedrine in the intraoperative setting. 13 In the present study, we tested whether the thirdgeneration FloTrac/Vigileo device allows tracking trends in CI induced either by volume expansion or by changes in the dose of norepinephrine in critically ill patients.
Methods

Subjects
After approval by the Institutional Review Board of our institution, subjects were enrolled if a volume expansion (20 subjects) or an increase (20 different subjects) or a decrease (20 different subjects) in the dose of norepinephrine was planned by the attending physician. Subjects' relatives were informed about the study at the time of enrolment with the possibility of refusing participation at that time. Subjects were informed as soon as their mental status allowed, and the possibility was given to withdraw their participation in the study.
All subjects had a catheter inserted into the internal jugular vein and a catheter inserted into the femoral artery (PV8215 monitoring kit, Pulsion Medical Systems, Munich, Germany). The arterial line was divided into two branches through a stopcock, one connected to a PiCCO2 device (Pulsion Medical Systems) and the other connected to a third-generation FloTrac/Vigileo device (Edwards Lifesciences, Irvine, CA, USA).
Measurements and study design
Before each therapeutic intervention, we performed a first set of haemodynamic measurements, including heart rate, systemic arterial pressure, CI measured by transpulmonary thermodilution (CI td ), CI measured by pulse-wave analysis by the third-generation FloTrac/Vigileo device (CI pw ), and SVR. We used the values of CI pw automatically displayed on the screen of the FloTrac/Vigileo device averaged over a 20 s rolling period. The CI td was measured by the PiCCO2 device by injecting 15 ml of iced saline (,108C) through the central venous line. The injection was performed in triplicate and the values of CI td were averaged. Immediately before performing thermodilution boluses, the value of CI pw was carried out. The CI pw was recorded immediately before thermodilution to avoid interference between temperature drift and accuracy of CI pw . The total SVR was calculated as SVR¼mean arterial pressure×80/(CI td ×body surface area).
After the first set of haemodynamic measurements was completed, volume expansion was performed (500 ml of saline over 30 min) or the dose of norepinephrine was increased or decreased. All other treatments were unchanged during the therapeutic interventions.
A second set of haemodynamic measurements was carried out again after the therapeutic intervention (i.e. at the end of fluid administration and 5 min after stabilization of mean arterial pressure). This set included heart rate, systemic arterial pressure, CI pw , CI td , and SVR. Comparisons between subjects receiving volume expansion, subjects in whom the dose of norepinephrine was increased, and subjects in whom the dose of norepinephrine was decreased were performed by a two-tailed Student's t-test or a MannWhitney U-test, as appropriate. Correlations were assessed by the Pearson coefficient and correlation coefficients were compared using the Fisher transformation.
Statistical analysis
14 This analysis was also separately performed in subjects in whom SVR changed in absolute value by more or less than 15% with the therapeutic interventions. 15 We compared the relative changes of CI pw with those of CI td during the therapeutic intervention by the Bland and Altman analysis (for absolute changes) and by linear regression analysis (for per cent changes). For assessing the trending ability of CI pw , we constructed a four-quadrant plot. 16 This allowed calculation of the percentage of total data points for which the direction changes of CI pw (increase or decrease) were concordant with CI td . Since the least significant change of CI td is 12% when three thermodilution measurements are performed, 17 we applied a 12% exclusion limit. We also constructed a receiver operating characteristic (ROC) curve to test the ability of changes in CI pw to detect an increase in CI td ≥12% induced by volume expansion. We calculated the percentage error of CI pw as 2× SD mean 21 of CI td . 18 A P value of ,0.05 was considered significant. The statistical analysis was performed using MedCalc8.1.0.0 software (Mariakerke, Belgium).
Results
Subject characteristics
Subject characteristics at baseline are summarized in Table 1 . Circulatory failure was of septic origin in the majority of subjects. All subjects received norepinephrine at baseline. Subjects deemed as receiving volume expansion received Third-generation FloTrac in critically ill patients norepinephrine at baseline and this dose was kept unchanged during the study period ( Table 2 ). The second set of measurements was recorded 32 (4) min after the first set in subjects receiving volume expansion and 35 (10) min after the first set in subjects in whom the dose of norepinephrine was changed. The area under the ROC curve constructed for the changes in CI pw for detecting an increase in CI td ≥12% was not significantly different from 0.5 (Fig. 3) .
Comparison of CI pw with CI td in subjects with a change in dose of norepinephrine
In subjects in whom the dose of norepinephrine was increased, mean arterial pressure, SVR, CI td , and CI pw significantly increased by 22 (25)%, 8 (28)%, 9 (21)%, and 20 (19)%, respectively (Table 2 ). In subjects in whom the dose of norepinephrine was decreased, mean arterial pressure, SVR, CI td , and CI pw significantly decreased by 15 (13)%, 8 (17)%, 9 (18)%, and 12 (12)%, respectively (Table 2) .
Considering subjects in whom norepinephrine was increased or decreased as one group (n¼40), the bias between the absolute changes in CI pw and CI td induced by norepinephrine decrease/increase was 0.11 (0.68) litre min 21 m 22 . The coefficient of determination (r 2 ) between the norepinephrine-induced per cent changes in CI pw and in CI td was 0.11 (P¼0.04) (Fig. 4) . The concordance rate between the changes in CI pw and CI td induced by changing the dose of norepinephrine was 60% (Fig. 4) . After the decrease/increase of norepinephrine dose, the bias between the absolute values CI pw and CI td was 20.30 (1.04) litre min 21 m 22 and the percentage error was 61%. Results concerning separate groups of subjects with an increase and a decrease in the dose of norepinephrine are shown in Table 3 .
Effects of changes in SVR on the agreement of CI pw with CI td
Considering the aggregate of all therapeutic interventions, changes in SVR ranged from 231% to +73%. The bias between changes in CI pw and CI td significantly correlated with changes in SVR (r 2 ¼0.41, P,0.0001).
In the subset of subjects in whom SVR (absolute value) changed by less than 15% (n¼33), the bias between the absolute changes in CI pw and CI td was 20.12 (0.43) litre min 21 m 22 . In these subjects, there was no significant correlation between SVR and bias between CI td and CI pw (P¼0.29).
In the subset of patients in whom the SVR (in absolute value) increased by more than 15% (n¼27), the bias between the absolute changes in CI pw and CI td was 0.22 (0.89) litre min 21 m 22 . In these patients, the coefficient of determination (r 2 ) between SVR and the per cent changes in CI td and CI pw was 0.49 (P,0.0001).
Discussion
The third-generation FloTrac/Vigileo device was not reliable for detecting trends in CI, especially when induced by norepinephrine. The higher the total SVR, the higher was the bias between CI measured by FloTrac/Vigileo and by transpulmonary thermodilution. Monitoring CO in critically ill patients is recommended when shock persists despite adequate fluid resuscitation. 19 A recent study also suggests that changes in arterial pressure are unable to reliably monitor the changes in CI induced by vasopressors, 20 reinforcing the message that CO should be measured in critically ill patients after initial fluid resuscitation. Among the several techniques that are currently available for measuring CI, the estimation of CI computed from arterial pressure waveform analysis has the advantage of providing beat-to-beat estimation of CI. In fact, three elements influence the relationship between the shape of the peripheral arterial wave and stroke volume: arterial compliance, arterial vasomotor tone, and pulse-wave amplification phenomenon. 1 Thus, estimation of CI by arterial pressure waveform analysis is based upon a geometric analysis of the shape of the arterial pressure curve which is then adjusted with a factor taking into account the arterial compliance and tone and the pulse-wave amplification phenomenon. 12 In a recent study, in septic shock patients, De Backer and colleagues 12 found that the third-generation FloTrac/Vigileo device is more accurate, as precise as, and less influenced by total SVR than the previous version. Consistent with this study, we found that the percentage error for CI pw recorded for all pairs of measurements was improved compared with results obtained with the second-generation system 11 (54% vs 61%, respectively). In contrast to De Backer and colleagues, we focused on the ability of the uncalibrated devices to follow changes in CI induced by some systematic therapeutic changes. Even though it was conducted in subjects with total SVR in the same range as those in the study of De Backer and colleagues, 12 the present study suggests that the most recent version of the FloTrac/Vigileo system does not provide a satisfactory track of therapy-induced changes in CO. First, even though changes in CI td and CI pw were more significantly correlated when induced by volume expansion than by norepinephrine, the third-generation FloTrac/Vigileo did not provide a correct estimation of the response to a standardized fluid challenge, as defined by an increase in CI td ≥15%. Second and more importantly, our results suggest that the new FloTrac/Vigileo device was not reliable for tracking trends in CI induced by changing the dose of norepinephrine. Moreover, by showing that the accuracy of the third-generation FloTrac/Vigileo device correlated with total SVR, we suggest that its estimation of CI is still distorted by a change in vascular tone. The ability to track norepinephrine-induced changes in CI seems to be improved compared with the previous version of the system. Indeed, in our previous study, 11 we did not find significant correlation between changes in CI pw and CI td induced by norepinephrine changes, while this correlation was significant in the present study (r¼0.35, P,0.05). This suggests substantial but insufficient improvements in the device software. Importantly, the present results are in accordance with two recent studies conducted in other clinical settings. In neurosurgical patients requiring high-dose vasopressor support, Metzelder and colleagues 25 showed that the introduction of the thirdgeneration FloTrac/Vigileo software algorithm did not improve the insufficient precision for CI measurements observed with the second software version. In a general population of anaesthetized subjects, Meng and colleagues 13 reported that the newest FloTrac/Vigileo generation accurately tracked changes in CO when preload changed but did not accurately track changes in CO induced with phenylephrine and ephedrine. We acknowledge some limitations to our study. First, we could not perform a direct comparison between the second and third generations of the FloTrac/Vigileo system since the previous version is no longer provided by the manufacturer. Secondly, as a reference for measuring CI, we used transpulmonary thermodilution rather than classical thermodilution with the pulmonary artery catheter. 26 Nevertheless, the accuracy of transpulmonary thermodilution in measuring CO has been repeatedly demonstrated. 15 23 27 -33 Thirdly, we did not test other systems that compute CI from the pressure waveform without external calibration, so our conclusions might not apply to these devices.
In conclusion, estimation of CI made from the thirdgeneration FloTrac/Vigileo device was only moderately reliable for detecting the changes in CI induced with volume expansion and did not allow tracking trends in CI provoked by changing the dose of norepinephrine in critically ill patients. As a clinical consequence, this study suggests that this device should be reserved for patients who are not receiving vasopressors. 
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